ExaGrid Named “Recommended” Solution for Deduplication Backup Target Appliances by DCIG
ExaGrid ®, a leading provider of hyper-converged secondary storage (HCSS) for backup with data deduplication, today announced that independent analyst firm DCIG once again ranked the ExaGrid disk-based backup appliance in the top category of “Recommended” in its recently published 2018 Deduplication Backup Target Appliance Buyer’s Guide. This body of research assists organizations in matching their business and technical requirements for disk-based backup to best available products.
“This is the fourth consecutive year that ExaGrid has earned top-most positions in the DCIG Buyer’s Guides, which continues to validate the power of our differentiated product architecture and the speed and reliability it delivers,” said Bill Andrews, CEO of ExaGrid. “We’re very proud of this continued distinction.”
DCIG’s analysts concluded that ExaGrid’s unique architecture that combines a landing zone and full appliances in a single scale-out system differentiates its solution from those of its competitors. According to Jerome Wendt, President & Lead Analyst at DCIG, “Enterprises need faster, more scalable, easier to manage deduplication backup target appliances that also accelerate recoveries than ever before. The ExaGrid EX40000E and EX32000, ranked as ‘Recommended’ in the DCIG 2018 Deduplication Backup Target Appliance Buyer’s Guide, exemplify these requirements. ExaGrid’s solutions provide enterprises with the features they need to meet and exceed their backup and recovery requirements while delivering the scalability and simplicity they expect.”
According to the report, ExaGrid’s scale-out architecture, unique landing zone, ongoing virtualization enhancements, and seamless deployments helped the EX40000E and EX32000E appliances place in the top category of “Recommended.” ExaGrid, with its scale-out backup storage and unique landing zone, is 3 times faster for ingest and over 20 times faster for restores and VM boots than its closest competitor. In addition, ExaGrid is the only solution that provides a fixed-length backup window as data grows. With ExaGrid, IT can have the fastest backups, restores, and VM boots; a fixed-length backup window; and the ability to easily scale their systems, so they simply buy what they need as they need it, all at the lowest cost up front and over time. ExaGrid eliminates forklift upgrades and product obsolescence.
The DCIG 2018 Deduplication Backup Target Appliance Buyer’s Guide drives time and cost out of the product selection process by enabling prospective buyers to more quickly identify a shortlist of products that meet their specific needs. Thus, prospective purchasers can focus their product evaluation energies and move more quickly to buying the best solution for them.
DCIG is a group of analysts with IT industry expertise who provide informed, insightful, third party analysis and commentary on IT hardware, software and services. DCIG independently develops and licenses access to DCIG Buyer's Guide Editions. DCIG Buyer's Guides provide actionable intelligence through comprehensive, in-depth analysis of data center infrastructure product features. DCIG also develops sponsored content in the form of blog entries, customer validations, product reviews, special reports and executive, standard and full-length white papers. DCIG's target audiences include C-level executives, IT managers, systems and storage engineers and architects, press/media, magazine and website editors, bloggers, financial and technical analysts, and cloud service providers. More information is available at http://www.dcig.com .
ExaGrid provides hyper-converged secondary storage for backup with data deduplication, a unique landing zone, and scale-out architecture. ExaGrid’s landing zone provides for the fastest backups, restores, and instant VM recoveries. Its scale-out architecture includes full appliances in a scale-out system and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades. Follow us @ExaGrid and LinkedIn, and visit exagrid.com. See what ExaGrid customers have to say about their own ExaGrid experiences and why they now spend significantly less time on backup.
ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.
Christine Murphy, 508-898-2872 x248
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers18.2.2018 00:00 | Tiedote
Celgene Corporation (NASDAQ:CELG) today announced that data from the phase III RELIEF™ clinical trial of OTEZLA® (apremilast) in patients with active Behçet’s Disease with oral ulcers were presented in a late-breaking oral presentation at the 2018 American Academy of Dermatology (AAD) Annual Meeting. The results showed statistically significant reductions in oral ulcers with apremilast 30 mg twice daily (BID) versus placebo through week 12. OTEZLA (apremilast) is Celgene’s oral selective inhibitor of phosphodiesterase 4 (PDE4). Behçet’s Disease is a rare, chronic, multi-system inflammatory syndrome. Oral ulcers, the most common manifestation of Behçet’s Disease, can be disabling and have a substantial effect on quality of life. This study primarily evaluated the effect of apremilast on recurring oral ulcers in patients with active Behçet’s Disease who were previously treated with at least one topical or systemic medication. “Reducing oral ulcers, which are painful and can negatively im
CT-P13 (biosimilar infliximab) is comparable to reference infliximab and adalimumab in highly anticipated real-world study17.2.2018 11:00 | Tiedote
Twelve-month data from the Personalised Anti-TNF therapy in Crohn’s disease Study (PANTS) was presented at the 13th Congress of the European Crohn’s and Colitis Organisation (ECCO). The results indicate that the clinical effectiveness, safety and immunogenicity of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) in patients with Crohn’s disease (CD) is comparable to those treated with reference infliximab as well as those treated with adalimumab.1 The UK-wide, three-year prospective observational study investigated primary non-response (PNR), loss of response (LOR) and adverse drug reactions (ADR) to infliximab (reference infliximab and CT-P13) and adalimumab in 1610 CD patients. The data show comparable efficacy between CT-P13, reference infliximab and adalimumab in relation to PNR, LOR and ADR rates. In addition, at week 54, the remission rate was 39.7%, 39.0% and 32.7% for reference infliximab, CT-P13 and adalimumab treated patients, respectively.1 The PANTS study investigates
Avanti Communications HYLAS 4 Satellite Arrives in French Guiana16.2.2018 21:26 | Tiedote
Avanti Communications Group plc (“Avanti”), a leading provider of satellite data communications services in Europe, the Middle East and Africa (“EMEA”), announces its HYLAS 4 satellite has arrived safely in French Guiana ahead of its March 2018 launch. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005586/en/ Avanti Communications HYLAS 4 Satellite Arrives in French Guiana (Photo: Business Wire) The spacecraft, built by Orbital ATK was packed and shipped at their Satellite Manufacturing Facility in Dulles, Virginia, United States and flown to French Guiana, where it was unloaded and will be taken to the Arianespace launch facilities in Kourou. HYLAS 4 uses the latest High Throughput Satellite technology, doubling Avanti's Ka-band capacity across EMEA. The latest addition to Avanti's HYLAS fleet will provide: Backhaul services for mobile network operators Wholesale broadband for ISPs Connectivity for governments (civil a
General Cable Corporation Stockholders Approve Acquisition By Prysmian Group16.2.2018 20:05 | Tiedote
General Cable Corporation (NYSE: BGC) today announced the voting results from the Company’s special meeting of stockholders held this morning. Stockholders of General Cable approved the Company’s previously announced acquisition by Prysmian Group (BIT: PRY) for $30.00 per share in cash. A total of 38,140,754 shares, representing approximately 75.34% of the total number of shares of common stock outstanding and approximately 99% of the total votes cast, were voted in favor of the merger. Subject to regulatory approvals and other customary closing conditions, the transaction is expected to close by the third quarter of 2018. About General Cable General Cable (NYSE:BGC), with headquarters in Highland Heights, Kentucky, is a global leader in the development, design, manufacture, marketing and distribution of aluminum, copper and fiber optic wire and cable products for the energy, communications, automotive, industrial, construction and specialty segments. General Cable is one of the larges
Systemic Sclerosis World Congress:Inspirational Patient Stories Reveal the Challenging Realities of Living with Devastating Rare Disease16.2.2018 12:03 | Tiedote
Boehringer Ingelheim today unveils a new phase of 'More Than Scleroderma: The Inside Story', and launches the new patient website www.morethanscleroderma.com. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005188/en/ Anna, 36, living with scleroderma (Photo: Business Wire) The global initiative highlights the importance of understanding the ‘inside story’ of each individual living with scleroderma, also known as systemic sclerosis. To coincide with the Systemic Sclerosis World Congress in Bordeaux, 15-17 February 2018, new and truly inspiring patient stories are revealed, reflecting the real-life, diverse and very moving journeys of people living with scleroderma across the world. The campaign will also be launched in the U.S. The new website www.morethanscleroderma.com features a powerful collection of photographs and video stories of people living with scleroderma across the world, revealing the life-changing impact o
Philip Morris International Recognized as a Global Top Employer for the Second Year in a Row16.2.2018 11:00 | Tiedote
Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today is recognized for the second year in a row as a Global Top Employer. This year’s certification from the Top Employer Institute is awarded to PMI teams in 44 countries, a testament to the company’s consistency and excellence in offering an enriching and dynamic work environment, and exceptional development opportunities for employees across the globe. PMI has been recognized by the Top Employer Institute for six consecutive years. This year, PMI was awarded with five regional certifications in Europe, the Middle East, Africa and, for the first time, in North America and Latin America. Additionally, Indonesia was the first PMI affiliate to be certified in Asia. “It is a proud moment for all of us at PMI,” said Charles Bendotti, PMI Senior Vice President, People and Culture. “Our success as a company relies on the men and women who come to work every day with a passion to achieve, and a willingness to learn, grow, and
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme